leisure time -WSS

leisure time

author：comprehensive 2025-09-30 18:34:58 - browse：77738

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Amid AI frenzy, a top HHS official's quest to create safeguards

hotspot

focus

knowledge

WSS

Alabama hospital puts IVF treatments on hold

How many hemophilia patients actually want gene therapy?

Alabama hospital puts IVF treatments on hold

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Obesity drugs seen as possible treatment for liver disease MASH

Steward Health Care Massachusetts hospitals face fiscal disaster

leisure time

leisure time

focus

In Memoriam: Notable people who died in 2023

Why scientists need input from humanists on sensitive research

What does generative AI mean for health care? We asked experts

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Medical leaders decry Supreme Court decision on affirmative action

John Green on his newest strategy for fighting tuberculosis

Tori Bowie and the unacceptable rates of Black maternal death

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Novavax promises a turnaround & Lilly roils the obesity market

NIH study of ME/CFS points to clear biological hallmarks

explore

Steward Health Care Massachusetts hospitals face fiscal disaster

Amid AI frenzy, a top HHS official's quest to create safeguards

Medicare coverage of Wegovy, once blocked, now looks possible

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

How to save health care price transparency rules

Amid AI frenzy, a top HHS official's quest to create safeguards

hotspot

focus

knowledge

hotspot